IQVIA Holdings Inc. $IQV Shares Sold by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. has decreased its stake in IQVIA Holdings Inc. by 1.6%, selling 57,684 shares, leaving it with approximately $623.46 million in the company.
• AQR Capital Management LLC and other hedge funds significantly increased their positions in IQVIA, with AQR boosting its stake by 58.1%, bringing its total to around $115.87 million.
• IQVIA's stock has an average rating of "Moderate Buy" among analysts, with a current price target average of $228.62, following a positive earnings report exceeding expectations.

Alliancebernstein L.P. cut its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,536,356 shares of the medical research company's stock after selling 57,684 shares during the period. Alliancebernstein L.P. owned 2.04% of IQVIA worth $623,460,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Continuum Advisory LLC lifted its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares during the period. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares in the last quarter. Independent Advisor Alliance increased its holdings in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares in the last quarter. ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. Finally, Nemes Rush Group LLC grew its holdings in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after buying an additional 81 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE:IQV traded up $3.67 during midday trading on Friday, hitting $187.75. 1,263,215 shares of the stock were exchanged, compared to its average volume of 1,128,696. The stock has a market cap of $31.92 billion, a P/E ratio of 27.17, a PEG ratio of 2.06 and a beta of 1.32. The company has a 50 day moving average price of $179.88 and a 200-day moving average price of $167.41. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $249.43. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Barclays boosted their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Mizuho boosted their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $229.86.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.